Repurposing dihydroartemisinin as a novel anticancer agent against colorectal cancer stem cells
Journal of Food and Drug Analysis · 17.09.2025 · 33 (3) · 276-290
DOI: 10.38212/2224-6614.3552 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Food and Drug Analysis, online erschienen am 17.09.2025. Verfasst von Meng-Han Wu und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, National Taiwan University, Taipei 10050, Taiwan. Hauptthemen laut MEDLINE: Neoplastic Stem Cells, Colorectal Neoplasms, Artemisinins, Antineoplastic Agents. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Colorectal cancer (CRC) is one of the leading causes of cancer-related death globally and discovering novel therapeuticagents to treat the disease, and prevent cancer metastasis and recurrence is an urgent medical need. Cancer stem cells(CSCs) capable of self-renewal and differentiation are generally considered the cause of tumor metastasis, recurrenceand chemoresistance. Hence, targeting CSCs may be a promising strategy for the treatment of cancer. GATA6, a zincfinger transcription factor, contributes to tumorigenesis in CRC and is related to cancer stemness. GATA6-overexpressing stable clones OE4 and OE6 derived from HCT116 cells were previously established and exhibitedincreased stemness properties. In this study, we found that OE4 and OE6 cells displayed CSC-like properties, includinghigher expression levels of stemness-related proteins, increased sphere forming capacity and resistance to 5-fluorouracil.OE4 and OE6 cells also showed increased glucose uptake capacity, another hallmark of CSCs. Therefore, these two cellclones were employed as a CSC-like cell model to search for potential colorectal CSC-targeting drugs. Among severalcompounds tested, dihydroartemisinin (DHA), an antimalarial drug, exerted better anticancer activity toward OE4 andOE6 relative to the empty vector-transfected HCT116 cells. DHA also inhibited sphere formation and impaired glucosemetabolism. DHA induced G0/G1 arrest and apoptosis. Moreover, DHA also induced reactive oxygen species andmitochondrial membrane potential loss. Thus, DHA caused mitochondrial damage which was confirmed by Seahorsemitochondrial stress test. DHA also increased LC3B-II and PINK1 protein levels, indicative of autophagy/mitophagy. Inconclusion, repurposing DHA may be a potential strategy against colorectal CSCs and further validation using in vivo models is warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, National Taiwan University, Taipei 10050, Taiwan.
- Institute of Biopharmaceutical Sciences, School of Pharmaceutical Sciences, National Yang Ming Chiao Tung University, Shi-Pai, Taipei 11221, Taiwan.
Zitieren
APA
Wu, M. H., Sung, C. J., Kung, F. L., Guh, J. H., Su, Y., & Hsu, L. C. (2025). Repurposing dihydroartemisinin as a novel anticancer agent against colorectal cancer stem cells. Journal of Food and Drug Analysis, 33(3), 276-290. https://doi.org/10.38212/2224-6614.3552
Vancouver
Wu MH, Sung CJ, Kung FL, Guh JH, Su Y, Hsu LC. Repurposing dihydroartemisinin as a novel anticancer agent against colorectal cancer stem cells. Journal of Food and Drug Analysis. 2025;33(3):276-290. doi:10.38212/2224-6614.3552
BibTeX
@article{Wu2025,
author = {Wu, Meng-Han and Sung, Chieh-Ju and Kung, Fan-Lu and Guh, Jih-Hwa and Su, Yeu and Hsu, Lih-Ching},
title = {Repurposing dihydroartemisinin as a novel anticancer agent against colorectal cancer stem cells},
journal = {Journal of Food and Drug Analysis},
year = {2025},
volume = {33},
number = {3},
pages = {276--290},
doi = {10.38212/2224-6614.3552}
}
EUVIMED